Sutro Biopharma (STRO) 주식 개요
는 종양학 회사로 운영되고 있습니다. 자세히 보기
STRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sutro Biopharma, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$29.99 |
| 52주 최고가 | US$43.85 |
| 52주 최저가 | US$7.15 |
| 베타 | 1.52 |
| 1개월 변동 | 16.29% |
| 3개월 변동 | 15.97% |
| 1년 변동 | 266.72% |
| 3년 변동 | -37.39% |
| 5년 변동 | -82.78% |
| IPO 이후 변동 | -80.27% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 29
STRO: Index Additions And ADC Pipeline Progress Will Drive Future Upside
Analysts have raised their fair value estimate for Sutro Biopharma from $51.00 to $61.00, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E levels as key drivers of the new price target. What’s in the News for Sutro Biopharma Sutro Biopharma was added to the Russell 2000 Index, increasing its visibility among small cap-focused index investors.
내러티브 업데이트 • Jun 15
STRO: ADC Pipeline And Equity Raise Will Drive Future Upside Potential
Analysts have slightly increased their price target on Sutro Biopharma to $48.31 from $48.17, citing refreshed assumptions around discount rates, revenue trajectory, margins, and a lower projected future P/E multiple. What's in the News Sutro Biopharma shared preclinical data at the American Association for Cancer Research Annual Meeting 2026 covering six presentations, including one oral session and five posters, focused on its next generation antibody drug conjugate pipeline.내러티브 업데이트 • Jun 01
STRO: ADC Pipeline Progress Will Drive Future Upside Potential
Analysts have raised their price target on Sutro Biopharma from about $32 to roughly $48, citing updated assumptions that include a slightly higher discount rate, a steeper projected revenue decline, a stronger profit margin profile, and a higher implied future P/E multiple. What's in the News Sutro Biopharma reported preclinical data for STRO-004, a tissue factor targeted ADC, showing robust antitumor activity and disease control across multiple TF expressing solid tumor patient derived xenograft models at a single 5 mg/kg dose, with a highest non severely toxic dose of 50 mg/kg and a pharmacokinetic profile that is expected to support higher drug exposure (Key Developments).분석 기사 • May 28
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders will have a reason to smile today, with the analysts making...Recent updates
내러티브 업데이트 • Jun 29
STRO: Index Additions And ADC Pipeline Progress Will Drive Future Upside
Analysts have raised their fair value estimate for Sutro Biopharma from $51.00 to $61.00, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E levels as key drivers of the new price target. What’s in the News for Sutro Biopharma Sutro Biopharma was added to the Russell 2000 Index, increasing its visibility among small cap-focused index investors.내러티브 업데이트 • Jun 15
STRO: ADC Pipeline And Equity Raise Will Drive Future Upside Potential
Analysts have slightly increased their price target on Sutro Biopharma to $48.31 from $48.17, citing refreshed assumptions around discount rates, revenue trajectory, margins, and a lower projected future P/E multiple. What's in the News Sutro Biopharma shared preclinical data at the American Association for Cancer Research Annual Meeting 2026 covering six presentations, including one oral session and five posters, focused on its next generation antibody drug conjugate pipeline.내러티브 업데이트 • Jun 01
STRO: ADC Pipeline Progress Will Drive Future Upside Potential
Analysts have raised their price target on Sutro Biopharma from about $32 to roughly $48, citing updated assumptions that include a slightly higher discount rate, a steeper projected revenue decline, a stronger profit margin profile, and a higher implied future P/E multiple. What's in the News Sutro Biopharma reported preclinical data for STRO-004, a tissue factor targeted ADC, showing robust antitumor activity and disease control across multiple TF expressing solid tumor patient derived xenograft models at a single 5 mg/kg dose, with a highest non severely toxic dose of 50 mg/kg and a pharmacokinetic profile that is expected to support higher drug exposure (Key Developments).분석 기사 • May 28
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • May 01
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
Summary Sutro Biopharma underwent major restructuring, including management changes, layoffs, and a 1-for-10 reverse split to maintain NASDAQ compliance. STRO's lead program, STRO-004, is a next-gen tissue factor-targeting exatecan ADC with a DAR of 8, aiming for Phase 1 data in mid-2026. Despite claims of improved safety via Fc-silencing and novel linker chemistry, prior ADCs (luveltamab tazevibulin) with similar strategies suffered high toxicities and discontinuation. Cash reserves and Vaxcyte equity holdings have dropped from ~$400M between 2023 to 2025 to $141.5M as of March 2026, raising sustainability concerns ahead of key clinical readouts. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 25
STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook
Analysts have raised their price target for Sutro Biopharma by about $2, reflecting updated fair value estimates along with revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Sutro reported promising preclinical data for multiple next generation antibody drug conjugates (ADCs), including STRO-004, STRO-006 and STRO-227, at the American Association for Cancer Research Annual Meeting 2026.내러티브 업데이트 • Apr 10
STRO: Equity Offering And Lockup Structure Will Support Future Upside
Analysts now place Sutro Biopharma's price target at about $30.11, up from roughly $27.88. This reflects updated assumptions around fair value, discount rate, future revenue trends, profit margin, and a higher future P/E of about 199x.내러티브 업데이트 • Mar 27
STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside
Analysts have revised their price target for Sutro Biopharma from $21.25 to $27.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E in their models. What's in the News Sutro Biopharma filed a follow-on equity offering of up to US$100 million in common stock as an at-the-market program, providing flexibility to issue shares over time.내러티브 업데이트 • Mar 10
STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential
Analysts have kept their $51.00 price target on Sutro Biopharma unchanged, as a slightly lower discount rate and a higher assumed future P/E multiple are seen as offsetting a softer revenue outlook and reduced profit margin expectations. What's in the News Sutro Biopharma completed a follow on equity offering of approximately US$110.0 million, issuing 7,868,383 common shares at US$13.98 per share with a US$0.8388 discount per share (Key Developments).내러티브 업데이트 • Feb 24
STRO: Reverse Split And Equity Raise Will Support Future Upside
Analysts have inched up their price target on Sutro Biopharma to $21.25 from $21, citing updated assumptions that include a slightly lower discount rate, modest changes to long term profit margin expectations, and a higher future P/E multiple. What's in the News Sutro Biopharma completed a follow on equity offering of common stock, raising about US$110.0m through the sale of 7,868,383 shares at US$13.98 per share, reflecting a US$0.8388 per share discount (Key Developments).내러티브 업데이트 • Feb 09
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their price target on Sutro Biopharma at US$51.00, making only minor adjustments to their models. Slightly softer assumptions for long-term revenue growth and profit margins are largely offset by a higher future P/E multiple.분석 기사 • Feb 04
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...내러티브 업데이트 • Jan 26
STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside
Analysts lifted their price target on Sutro Biopharma to US$51.00 per share, highlighting updated assumptions around fair value, discount rate, revenue growth expectations, profit margins, and a slightly lower future P/E as the key drivers of the change. What's in the News Sutro Biopharma regained compliance with Nasdaq’s continued listing standard for minimum share price under Rule 5450(a)(1) after its common stock maintained an average closing price of at least US$1.00 following a 1:10 reverse stock split effective December 3, 2025 (company announcement).내러티브 업데이트 • Jan 10
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside
Analysts have trimmed their price target on Sutro Biopharma from US$22.29 to US$21.00, citing updated assumptions that include a slightly lower discount rate, a wider expected revenue decline of about 6.3 percentage points, a modestly higher profit margin, and a higher future P/E multiple. What's in the News Sutro Biopharma was removed from the Nasdaq Biotechnology Index, which can affect index fund ownership that tracks this benchmark (Index Constituent Drops).분석 기사 • Dec 31
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders would be excited to see that the share price has had a great month...내러티브 업데이트 • Dec 17
STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside
Narrative Update on Sutro Biopharma Analysts have reduced their price target on Sutro Biopharma from approximately $28.00 to about $22.30 per share. This reflects a lower assumed future price to earnings multiple, while expectations for revenue growth and profit margins remain largely unchanged.내러티브 업데이트 • Dec 03
STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside
Analysts have raised their price target on Sutro Biopharma from 2.69 dollars to 28.00 dollars, citing expectations for improved long term profit margins despite softer revenue growth assumptions and a modestly higher discount rate. What's in the News Sutro Biopharma approved a 1 for 10 reverse stock split or significant stock dividend effective December 3, 2025, aimed at improving its share price profile for investors (company announcement).내러티브 업데이트 • Sep 10
ADC Pipeline Focus Will Advance Preclinical Drug Development
The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69. What's in the News Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.분석 기사 • Jul 01
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Apr 18
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 36% in the last...
새로운 내러티브 • Apr 03
ADC Pipeline Focus Will Advance Preclinical Drug Development
Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.분석 기사 • Mar 04
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%
To the annoyance of some shareholders, Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares are down a considerable 25% in the...Seeking Alpha • Jan 02
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Summary STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution. Casting a wider net in pivotal trials carries risks but could expand patient eligibility, enhancing the overall investment thesis. Read the full article on Seeking Alpha분석 기사 • Nov 30
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 26% in the last...분석 기사 • Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
The Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Sep 23
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Summary STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments. In my view, STRO's valuation appears cheap relative to its potential. It has ample resources to fund operations and research, making it a "strong buy" despite inherent biotech risks. Read the full article on Seeking Alpha분석 기사 • Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 29% after a shaky period...분석 기사 • Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...분석 기사 • Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Sutro Biopharma, Inc. ( NASDAQ:STRO ) defied analyst predictions to release its quarterly results, which were ahead of...분석 기사 • Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 28% in the last...분석 기사 • May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Salary of US$686.7k is part of CEO Bill...분석 기사 • Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Market forces rained on the parade of Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders today, when the analysts...분석 기사 • Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
With a price-to-sales (or "P/S") ratio of 2x Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be sending very bullish signals...분석 기사 • Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 43% after a shaky period...분석 기사 • Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...주주 수익률
| STRO | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -1.4% | 3.4% | -0.4% |
| 1Y | 266.7% | 37.9% | 18.4% |
수익률 대 산업: STRO은 지난 1년 동안 37.9%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: STRO은 지난 1년 동안 18.4%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| STRO volatility | |
|---|---|
| STRO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: STRO의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: STRO의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2003 | 133 | Jane Chung | www.sutrobio.com |
수트로 바이오파마는 종양학 회사로 운영되고 있습니다. 이 회사는 독점적인 통합 무세포 단백질 합성 플랫폼인 XpressCF와 부위별 결합 플랫폼인 XpressCF+를 가능하게 하는 부위별 및 새로운 형식의 항체 약물 접합체(ADC)를 개발합니다. 주요 제품 후보로는 비소세포폐암, 두경부 편평세포암, 자궁경부암, 대장암, 췌관 선암, 자궁내막암, 방광암 등 TF 발현 고형 종양 치료를 위한 조직 인자(TF) 표적 ADC인 STRO-004가 있습니다.
Sutro Biopharma, Inc. 기초 지표 요약
| STRO 기초 통계 | |
|---|---|
| 시가총액 | US$527.60m |
| 순이익 (TTM) | -US$153.60m |
| 매출 (TTM) | US$99.61m |
5.0x
주가매출비율(P/S)-3.2x
주가수익비율(P/E)STRO는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| STRO 손익계산서 (TTM) | |
|---|---|
| 매출 | US$99.61m |
| 매출원가 | US$164.93m |
| 총이익 | -US$65.33m |
| 기타 비용 | US$88.28m |
| 순이익 | -US$153.60m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -9.27 |
| 총이익률 | -65.58% |
| 순이익률 | -154.21% |
| 부채/자본 비율 | 0% |
STRO의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/09 01:48 |
| 종가 | 2026/07/09 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sutro Biopharma, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Lukas Shumway | Barclays |
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |